Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Receives FDA Clearance for C. Diff Assay

NEW YORK (GenomeWeb) – Luminex said today that the US Food and Drug Administration has given 510(k) clearance for the firm's Aries C. difficile assay — a moderate complexity, sample-to-answer test for rapid detection of Clostridium difficile, which has become a common microbial cause of healthcare-associated infections in US hospitals.

In testing for C. difficile, the real-time PCR assay running on the Aries system detects both toxin A and toxin B, which may reduce the probability of a false negative result from strains that only produce toxin A, the firm said. 

"With this regulatory approval, we are further broadening our infectious diseases testing portfolio and adding to our rapidly growing menu of targeted assays and customized panels," Luminex President and CEO Homi Shamir said in a statement.

Earlier this year, Luminex received regulatory clearances for additional assays on Aries, including FDA clearances for Bordetella and Group B Streptococcus, and CE marking for Norovirus.

Ray Widen, scientific director of esoteric testing and R&D at Tampa General Hospital, said that the Aries C. difficile assay "was easy to use and performed very well in our lab during the clinical trial." He added that a combination of attributes — including a simple workflow for ease of training, sample in-answer out capabilities, and rapid time-to-result — makes the Aries system a good fit for routine microbiology laboratories "that may not have prior experience with molecular assays."

Citing a 2015 Centers for Disease Control and Prevention study, Luminex said that C. difficile caused almost half a million infections and 15,000 deaths among US patients in a single year.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.